PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE) Article

Stewart, Michael W, Rosenfeld, Philip J, Penha, Fernando M et al. (2012). PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE) . RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 32(3), 434-457. 10.1097/IAE.0B013E31822C290F

International Collaboration

cited authors

  • Stewart, Michael W; Rosenfeld, Philip J; Penha, Fernando M; Wang, Fenghua; Yehoshua, Zohar; Bueno-Lopez, Elena; Lopez, Pedro F

sustainable development goals

authors

publication date

  • March 1, 2012

webpage

published in

keywords

  • FACTOR THERAPY
  • LUCENTIS
  • Life Sciences & Biomedicine
  • MACULAR DEGENERATION
  • Ophthalmology
  • Science & Technology
  • VEGF Trap
  • VERTEPORFIN
  • aflibercept
  • anti-VEGF therapy
  • bevacizumab
  • biologic activity
  • dosing interval
  • intravitreal injection
  • pharmacokinetics
  • ranibizumab

Digital Object Identifier (DOI)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

start page

  • 434

end page

  • 457

volume

  • 32

issue

  • 3